Diagnostics

Study shows promising use of proteomics and bioinformatics in ovarian cancer detection

Published in Medical Letter on the CDC and FDA, March 17th, 2002

Results of a study published in the The Lancet show that a new method of assessing protein patterns in blood samples was able to detect 100% of ovarian cancer cases, even at the elusive early stage when the cancer is most survivable.

In an analysis of 116 blinded blood samples - 50 from patients with cancer and 66 with nonmalignant disease - the researchers were able to correctly identify all 50 cases of ovarian cancer, including, most significantly, all 18 stage I cases. Of the controls, 63 of the 66 (95%) were identified as noncancer. This is a vast improvement over the currently used ovarian cancer detection technique of identifying the tumor marker CA125...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2002-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry